Cargando…

Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer

Sequential treatment with endocrine or chemotherapy is generally used in the treatment of estrogen receptor (ER)-positive recurrent breast cancer. To date, few studies have investigated the effect of long-term endocrine therapy on the response to subsequent chemotherapy in ER-positive breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Takayuki, Oba, Takaaki, Tanimoto, Keiji, Shibata, Tomohiro, Kamijo, Shinobu, Ito, Ken-ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186817/ https://www.ncbi.nlm.nih.gov/pubmed/34101751 http://dx.doi.org/10.1371/journal.pone.0252822

Ejemplares similares

The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
por: Ono, Mayu, et al.
Publicado: (2021)

Lipid-rich carcinoma of the breast that is strongly positive for estrogen receptor: a case report and literature review
por: Oba, Takaaki, et al.
Publicado: (2016)

Estrogen Receptor Expression and Estrogen Receptor‐independent Cytotoxic Effects of Tamoxifen on Malignant Rhabdoid Tumor Cells in vitro
por: Koshida, Shigeki, et al.
Publicado: (2002)

Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer
por: Tsukamoto, Fumine, et al.
Publicado: (2021)

Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition
por: Oba, Takaaki, et al.
Publicado: (2018)

ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines
por: Oba, Takaaki, et al.
Publicado: (2016)

The Advantage of Using an Optical See-Through Head-Mounted Display in Ultrasonography-Guided Needle Biopsy Procedures: A Prospective Randomized Study
por: Shimizu, Tadafumi, et al.
Publicado: (2023)

FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer
por: Wang, Jinhua, et al.
Publicado: (2016)

Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen
por: Zhang, Jun, et al.
Publicado: (2018)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells
por: Miura, Kentaro, et al.
Publicado: (2019)

Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions
por: Wen, Jie, et al.
Publicado: (2008)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen‐sensitive breast cancer: A systematic review and meta‐analysis
por: Yoshida, Tsukasa, et al.
Publicado: (2023)

Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Partial Inhibition of Estrogen-Induced Mammary Carcinogenesis in Rats by Tamoxifen: Balance between Oxidant Stress and Estrogen Responsiveness
por: Singh, Bhupendra, et al.
Publicado: (2011)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models
por: Zou, Wei, et al.
Publicado: (2015)

Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells
por: Rotolo, Sabrina, et al.
Publicado: (2008)

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
por: Han, Wonshik, et al.
Publicado: (2006)

Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells
por: Ohno, Koichi, et al.
Publicado: (2022)

Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen
por: Bordeaux, Jennifer M., et al.
Publicado: (2012)

miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets
por: Klinge, Carolyn M.
Publicado: (2015)

Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice
por: Zhang, Zhi, et al.
Publicado: (2021)

Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer
por: Peng, Wan-Xin, et al.
Publicado: (2021)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer
por: Oba, Takaaki, et al.
Publicado: (2020)

Tamoxifen Regulates Cell Fate Through Mitochondrial Estrogen Receptor Beta in Breast Cancer
por: Razandi, Mahnaz, et al.
Publicado: (2012)

Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen
por: CHEN, MING, et al.
Publicado: (2013)

The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
por: Chang, Bo Yoon, et al.
Publicado: (2011)

Microarray Analysis on Gene Regulation by Estrogen, Progesterone and Tamoxifen in Human Endometrial Stromal Cells
por: Ren, Chun-E, et al.
Publicado: (2015)

Structure-Activity Relationships for the Antifungal Activity of Selective Estrogen Receptor Antagonists Related to Tamoxifen
por: Butts, Arielle, et al.
Publicado: (2015)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptors
por: Koulisis, Nicole, et al.
Publicado: (2016)

Influence of Tamoxifen‐Medroxyprogesterone Sequential Therapy on Estrogen and Progesterone Receptor Contents of Breast Cancer
por: Noguchi, Shinzaburo, et al.
Publicado: (1989)

Identification and Analysis of Estrogen Receptor α Promoting Tamoxifen Resistance-Related lncRNAs
por: Zhang, Xiulei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ifluciaa02sui5im4no0erd8vp